Introduction
============

Osteoarthritis (OA) is a common form of arthritis, a disease of the joints, considered the leading cause of disability worldwide ([@b1-etm-0-0-6261]). Kashin-Beck disease (KBD) is an endemic OA, prevailing in China, Eastern Siberia, and North Korea ([@b2-etm-0-0-6261]). OA and KBD not only affect physical function, but also cause emotional stress to patients ([@b3-etm-0-0-6261]). Although OA and KBD have similar clinical features, such as common articular cartilage lesions and chronic pain, the pathogenesis is quite different. KBD is characterized by degeneration and necrosis in the deep zone of articular cartilage and epiphyseal plate cartilage, whereas in OA, progressive articular cartilage degeneration and synovial inflammation are the major pathological processes ([@b4-etm-0-0-6261]). OA is more common in the elderly, whereas KBD typically affects children and adolescents ([@b3-etm-0-0-6261]). A clear understanding of the molecular mechanisms underlying both OA and KBD remains elusive, and prevents the development of effective therapeutic strategies.

Cartilage is composed of chondrocytes and the extracellular matrix (ECM). Chondrocytes have a strong biological activity and can differentiate and hypertrophy ([@b5-etm-0-0-6261]). The ECM has an important role in cartilage regeneration and degradation ([@b5-etm-0-0-6261]). The family of matrix metalloproteinases (MMPs) has been reported as the primary factor in arthritis ([@b6-etm-0-0-6261]). Integrin, as a transmembrane receptor, mediates the connection between the cell and its external environment (such as the ECM) ([@b5-etm-0-0-6261]). Therefore, when MMP activity is abnormal, the function of chondrocytes will inevitably be affected through integrins ([@b7-etm-0-0-6261],[@b8-etm-0-0-6261]). In OA, cartilage may contain excessive numbers of hypertrophy-like chondrocytes ([@b9-etm-0-0-6261]); however, chondrocytes can exhibit dedifferentiation in KBD. Although the two diseases have certain differences, there is no doubt that chondrocyte hypertrophy is abnormal in both OA and KBD. Furthermore, OA and KBD are oxidative-stress-associated diseases. In affected joints, oxidative DNA damage occurring in chondrocytes accumulates with OA progression ([@b10-etm-0-0-6261]).

In a previous study, 4-hydroxy-2-nonenal and 8-hydroxydeoxyguanisine were demonstrated to accumulate in the articular cartilage of KBD patients ([@b11-etm-0-0-6261]). A generator of peroxynitrite (ONOO^−^) in an aqueous solution, 3-morpholinosydnonimine (SIN-1), has been widely used in studies on oxidative or nitrosative stress ([@b12-etm-0-0-6261],[@b13-etm-0-0-6261]). Considering the instability of authentic ONOO^−^ at physiological pH, SIN-1 was chosen as an NO donor in the present study. Although numerous studies have been performed on deregulated hypertrophic differentiation and oxidative stress in chondrocytes of joint cartilages, studies that explore the exact molecular mechanism of oxidative stress in hypertrophic chondrocytes have not been published in recent years. In the present study, expression of osteogenesis genes was detected in hypertrophic chondrocytes treated with SIN-1 using chip array, and the interactions between these deregulated genes and how signaling factors change in OA was discussed. These data will provide new insights into the pathogenesis of OA and KBD.

Materials and methods
=====================

### Cell culture and establishment of the hypertrophic chondrocyte model

The murine chondrogenitor cell line ATDC5 is internationally used to study cartilage differentiation *in vitro*, and has previously been applied to set up a hypertrophic chondrocyte model ([@b14-etm-0-0-6261]). For the present study, the ATDC5 cell line was purchased from the European Collection of Cell Cultures (Salisbury, UK). ATDC5 cells were cultured in a 1:1 mixture of Dulbecco\'s modified Eagle\'s medium and Ham\'s F-12 medium (DMEM/F-12 medium; Hyclone; GE Healthcare Life Sciences, Logan, UT, USA), supplemented with 5% fetal bovine serum (FBS; Hyclone; GE Healthcare Life Sciences), penicillin (100 U/ml; Hyclone; GE Healthcare Life Sciences), and streptomycin (100 µg/ml; Hyclone; GE Healthcare Life Sciences). The cells were maintained at 37°C. ATDC5 cells were driven to hypertrophy using Insulin-Transferrin-Selenium (ITS) differentiation medium \[DMEM/F-12 containing 5% FBS, penicillin (100 U/ml), streptomycin (100 µg/ml) and 1% ITS (cat. no. 354352; BD Biosciences, Franklin Lakes, NJ, USA)\]. The ITS differentiation medium was changed every other day.

### Identification of the hypertrophic chondrocyte model via reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

ATDC5 cells were seeded at a density of 4×10^4^ cells/well in a six-well plate. Total RNA was isolated at 7, 14 and 21 days following ITS addition, using an RNeasy Plus Mini Kit (cat. no. 74104; Qiagen GmbH, Hilden, Germany). The concentration and purity of total RNA were determined by spectrophotometric measurement on a NanoDrop ND-2000 (NanoDrop; Thermo Fisher Scientific, Inc., Wilmington, Delaware, USA). A total of 1 µg of total RNA from each sample was reverse transcribed using a Revert Aid™ First cDNA Synthesis Kit (cat. no. K1622; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and the resulting cDNA was diluted five times in nuclease-free water. Type X collagen (Col X) and runt-related transcription factor 2 (Runx2), as marker genes of hypertrophy, were assessed during the induction of hypertrophy in ATDC5 cells using the QuantiFast SYBR Green PCR kit (cat. no. 204054; Qiagen GmbH, Hilden, Germany). The thermocycling conditions were as follows: One cycle at 95°C for 10 min; 40 cycles at 95°C for 5 sec, 60°C for 10 sec and 72°C for 10 sec. GAPDH mRNA served as an endogenous control. The synthetic oligonucleotide primers (Shanghai Boya Biotechnology Co., Ltd., Shanghai, China) for RT-qPCR are presented in [Table I](#tI-etm-0-0-6261){ref-type="table"}. The relative mRNA expression of the target genes were calculated using relative quantification (2^−ΔΔCq^) ([@b15-etm-0-0-6261]).

### Identification of the hypertrophic chondrocyte model by a western blotting assay

Proteins were harvested at 7, 14 and 21 days following ITS addition using radioimmunoprecipitation assay reagent (Beyotime Institute of Biotechnology, Haimen, China). Proteins were measured using a BCA kit (Beyotime Institute of Biotechnology). The protein levels of Col X and Runx2 were measured by western blotting. Equal amounts (20 µg) of total protein were separated by 10% SDS-PAGE, and were then transferred to an Immobilon polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA). Following blocking in 5% skimmed milk for 30 min at room temperature, the membranes were incubated with primary antibodies against Col X (1:200; cat. no. ab58632; Abcam, Cambridge, UK), Runx2 (1:1,000; cat. no. 12556; Cell Signaling Technology, Inc., Danvers, MA, USA) and GAPDH (1:500; Boster Biological Technology, Pleasanton, CA, USA) for 40 min at 37°C and then overnight at 4°C. After washing, the secondary antibody \[horseradish peroxidase (HRP)-conjugated anti-rabbit antibody (1:10,000; cat. no. 120745; Jackson ImmunoResearch Laboratories Inc, West Grove, PA, USA)\] was incubated for 30 min at 37°C. Following washing, the membrane was reacted with the Immobilon Chemiluminescent HRP substrate (EMD Millipore) in accordance with the manufacturer\'s protocol. Images were captured and analyzed by means of the SuperSignal Ultra Western blot chemiluminescence system (Gene Co., Ltd., Hong Kong, China).

### MTT assay to determine suitable SIN-1 concentration and incubation time

ATDC5 cells were seeded in a 96-well plate (1×10^3^ cells/well) and the ITS differentiation medium was used from the next day-day 21. The medium was changed every other day. Cells were incubated with 0, 1, 5 and 10 mM SIN-1 for 4 h, or 0, 1, 2, 3, 4 or 5 mM SIN-1 for 24 h at 37°C, and then further incubated for another 4 h in medium containing 0.5 mg/ml MTT (MP Biomedicals, LLC, Santa Ana, CA, USA) at 37°C. The cell culture medium was discarded and the intracellular purple formazan in each well was dissolved in 150 µl dimethyl sulfoxide. The purple crystals were quantified by measuring the absorbance at a wavelength of 490 nm in a microplate reader (3550; Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### RNA preparation for PCR array analysis

Total RNA from hypertrophic chondrocytes stimulated by 0 or 3 mM SIN-1 for 24 h was isolated using the RNeasy Plus Mini Kit (Qiagen GmbH). The concentration and purity of total RNA were measured, and RNA quality and integrity were evaluated by 2% agarose gel electrophoresis. cDNA was synthesized from 1 µg total RNA from each sample with the RT^2^ First Strand Kit (cat. no. 330401; Qiagen GmbH). Eliminating genomic DNA contamination with the RT^2^ Profiler PCR Array was essential for obtaining optimal real-time gene expression profiling results. The mixed sample was incubated at 42°C for 15 min and 95°C for 5 min. A total of 91 µl RNase-free water was added to each 20 µl cDNA synthesis reaction. The samples were mixed by pipetting up and down several times. The mixtures were kept on ice until the PCR procedure or stored at−20°C until processing.

### Liquid chip analysis using RT^2^ Profiler PCR Arrayss^®^

The 102 µl cDNA synthesis reaction was diluted with 1,248 µl RNase-free water and then added to 1,350 µl RT^2^ qPCR SYBR Green Mastermix (cat. no. 330522; Qiagen GmbH). A total of 25 µl PCR master mix was dispensed into each well of the 96-well Mouse Osteogenesis RT^2^ Profiler PCR Array (cat. no. PAMM-026Z; Qiagen GmbH). qPCR was performed on a Thermal Cycler Dice Real Time System (TP-800; Takara Bio, Inc., Otsu, Japan) via SYBR Green detection, and the following thermal cycling program: 1 cycle at 95°C for 10 min; 40 cycles of 95°C for 15 sec, 55°C for 40 sec, and 72°C for 30 sec; and 1 cycle at 95°C for 15 sec, 60°C for 30 sec and 95°C for 15 sec. All data from the real-time instrument were interpreted via the PCR Array Data web tool (<https://www.qiagen.com/cn/shop/genes-and-pathways/data-analysis-center-overview-page/?akamai-feo=off>; SABiosciences; Qiagen GmbH).

### Statistical analysis of PCR array data

Each PCR array included 5 housekeeping genes (Actb, B2m, GAPDH, Gusb, and Hsp90ab1) for normalization of the sample data. According to the manusfacturer\'s instructions of the aforementioned Mouse Osteogenesis RT^2^ Profiler PCR Array, if the Cq value of Mouse Genomic DNA Contamination (MGDA) control was \>30, then no genomic DNA contamination was detectable. Although the PCR array was performed only once, the fold changes and P-values were calculated by means of the PCR Array Data web tool.

### RT-qPCR validation

RT-qPCR was conducted to validate PCR array data. A total of 8 genes were selected, including 7 downregulated genes (Smad1-4, ColX, Vcam1 and MMP10) and 1 upregulated gene (Col2a1). The samples were prepared in the same way as described above. Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen GmbH). A total of 1 µg total RNA from each sample was reverse-transcribed with the Revert Aid™ First cDNA Synthesis kit (cat. no. K1622; Thermo Fisher Scientific, Inc.), and the resulting cDNA was diluted 5 times. GAPDH expression served as an endogenous control to normalize all samples for potential variations in mRNA content. The synthetic oligonucleotide primers for qPCR are presented in [Table I](#tI-etm-0-0-6261){ref-type="table"}. Single-stranded cDNA was amplified with the QuantiFast SYBR Green PCR Kit (cat. no. 204054; Qiagen GmbH). The thermal cycling program was the same as that in the PCR array experiment. The relative mRNA expression levels of the target genes were calculated using relative quantification (2^−ΔΔCq^) ([@b15-etm-0-0-6261]).

### Analysis of protein-protein interactions (PPIs), gene ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment

In the present study, PPIs, GO functions and KEGG pathway enrichment of 40 differentially expressed genes were analyzed in the STRING 10.05 software (<https://string-db.org/>) to understand their biological processes, molecular function, cellular components, KEGG pathways as well as their interactions at the protein level. The parameters of the reliability and the additional nodes could be adjusted according to the concrete analysis results. The PPI networks were constructed. A gene-pathway network analysis was conducted using Cytoscape 3.4.0 (<http://www.cytoscape.org/>).

### Statistical analysis

All data were expressed as the mean ± standard deviation and analyzed using SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA). Differences between two sampled were analyzed using Student\'s t-test. Data with more than two comparisons were analyzed using one-way analysis of variance followed by post hoc Fisher\'s least significant difference test or Bonferroni\'s multiple-comparison test, as required. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Establishment of the hypertrophic chondrocyte model

During the induction of hypertrophy, mRNA expression of Col X was significantly upregulated (P\<0.05) and it peaked on day 21 (P\<0.05; [Fig. 1A](#f1-etm-0-0-6261){ref-type="fig"}). The mRNA expression of Runx2 was also significantly changed (P\<0.05); it increased significantly on day 21 (P\<0.05), but decreased on day 14 (P\<0.05) compared with day 7 (P\<0.05; [Fig. 1B](#f1-etm-0-0-6261){ref-type="fig"}). Concurrently, protein expression levels of Col X and Runx2 also markedly increased on day 21, according to western blotting. Representative data from three independent experiments are presented ([Fig. 1C and D](#f1-etm-0-0-6261){ref-type="fig"}). Thus, culturing ATDC5 cells for 21 days to set up the hypertrophic chondrocyte model was carried out for all subsequent experiments.

### The effect of SIN-1 on vitality of hypertrophic chondrocytes

Subsequently, 0, 1, 5 or 10 mM SIN-1 was added to hypertrophic chondrocytes for 4 h incubation and cellular viability was measured via the MTT assay. All SIN-1 concentrations significantly decreased the cell viability (P\<0.05). The results demonstrated a high degree of toxicity with 10 mM SIN-1 P\<0.05; [Fig. 2A](#f2-etm-0-0-6261){ref-type="fig"}). Subsequently, 0, 1, 2, 3, 4 or 5 mM SIN-1 was added to hypertrophic chondrocytes for 24 h incubation and cell viability was measured via the MTT assay. All SIN-1 concentrations significantly decreased the cell viability (P\<0.05). There was a significant negative association between cellular viability and SIN-1 concentration, and 3 mM SIN-1 decreased viability by 50% (P\<0.05; [Fig. 2B](#f2-etm-0-0-6261){ref-type="fig"}). Therefore, 3 mM SIN-1 treatment was selected for 24 h as the standard procedure for the subsequent experiments.

### Differentially expressed genes in the chip array

In the PCR array, a total of 84 genes associated with osteogenesis were compared between the control and 3-mM SIN-1 group in hypertrophic chondrocytes. A scatter plot of 84 genes indicated that 40 genes were differentially expressed by 3-fold or greater ([Fig. 3](#f3-etm-0-0-6261){ref-type="fig"}). In total, 34 genes were downregulated ([Table II](#tII-etm-0-0-6261){ref-type="table"}), which were mostly associated with collagen, gene expression regulation (transcription factors), skeletal development, bone mineral metabolism and cell adhesion. A total of 6 genes were upregulated ([Table III](#tIII-etm-0-0-6261){ref-type="table"}), which were mostly associated with collagen, skeletal development and cell adhesion molecules.

### mRNA levels of 9 associated genes in experimental hypertrophic chondrocytes

To further confirm these PCR array data, 8 differentially expressed genes (Smad1-4, Col X, MMP10, Vcam1, and Col2a1) were validated in hypertrophic chondrocytes treated with 0 or 3 mM SIN-1. The RT-qPCR results demonstrated that 3 mM SIN-1 induced Smad1-4, Col X, MMP10, and Vcam1 downregulation and Col2a1 upregulation ([Fig. 4](#f4-etm-0-0-6261){ref-type="fig"}). These results are consistent with and support the reliability of the PCR array findings.

### Transforming growth factor (TGF)-β signaling cascades are the key pathways in hypertrophic chondrocytes treated with SIN-1

The results of PPI analysis demonstrated that there were four clusters in the PPI network ([Fig. 5](#f5-etm-0-0-6261){ref-type="fig"}). The most important cluster included TGF-βs \[TGF-β2 and TGF-β receptors (TGF-βr1 and−2)\], bone morphogenic proteins (BMPs; BMP2,−3, and−5, and BMP receptors 1A and 1B) and mothers against decapentaplegic homologs (Smads; Smad3 and−4), which were beneficial for the elucidation of biological systems participating in the oxidative stress in hypertrophic chondrocytes. KEGG pathway enrichment results ([Table IV](#tIV-etm-0-0-6261){ref-type="table"}) also demonstrated that TGF-β signaling cascades were the key pathways in hypertrophic chondrocytes treated with SIN-1, indicating that TGF-β/Smad signaling and BMP/Smad signaling were potential pathways associated with the above process. Once again, the gene-pathway network analysis yielded results similar to the above findings ([Fig. 6](#f6-etm-0-0-6261){ref-type="fig"}).

Discussion
==========

The oxidative stress in hypertrophic chondrocytes is regulated by multiple intricate signal transduction pathways. The crosstalk among these signals has a fine balance in normal hypertrophic chondrocytes ([@b16-etm-0-0-6261]). Free radicals, called 'the second messengers,' may adjust the expression of relevant target proteins through nuclear transcription factors and regulate chondrocyte growth, differentiation, and maturation ([@b17-etm-0-0-6261],[@b18-etm-0-0-6261]). In the normal physiological state, there is a dynamic balance between the free-radical-generating system and the scavenging system ([@b19-etm-0-0-6261]). Once excessive free radicals are produced or ingested, the original balanced state is disrupted and then causes cell damage ([@b20-etm-0-0-6261]). On the basis of previous research findings that implicated oxidative damage in the hypertrophy of chondrocytes in OA and KBD ([@b14-etm-0-0-6261],[@b21-etm-0-0-6261]), the present study was designed to profile altered gene expression of the intricate signaling network associated with oxidative stress to mimic cellular responses within an articular joint affected by OA or KBD.

In the present study, the TGF-β (*TGF-β1, −2* and -*3*, and *TGF-βr1,−2* and -*3*) and Smad (*Smad1-5*) families of genes. A total of 7 genes were downregulated in hypertrophic chondrocytes following treatment with SIN-1, including *TGF-β2, TGF-βr1, TGF-βr2, Smad1, Smad2, Smad3*, and *Smad4*. Smads are the downregulated gene targets of the TGF-β family of genes. TGF-β transduces signals from the cell membrane to the nucleus via its receptors and Smad proteins ([@b22-etm-0-0-6261]). In a European patient cohort, a single nucleotide polymorphism in the intron region of the *Smad3* gene has been demonstrated to be associated with hip and knee OA ([@b23-etm-0-0-6261]). TGF-β may stimulate chondrocyte matrix production and has been demonstrated to promote cartilage repair to alleviate OA ([@b24-etm-0-0-6261]). TGF-β/Smad3 signals could repress chondrocyte hypertrophic differentiation, and are essential for maintaining articular cartilage ([@b22-etm-0-0-6261]). TGF-β3 and phosphorylated Smad2 levels were significantly reduced in two murine models of osteoarthritis, accompanied by a loss of proteoglycans ([@b25-etm-0-0-6261]). In analyses of PPIs, KEGG pathway enrichment and gene-pathway network in the present study, it was demonstrated that TGF-β signaling cascades were the key pathways in hypertrophic chondrocytes treated with SIN-1. In accordance with previous results, the present study indicates that these differentially expressed TGF-β- and Smad-family genes may provide novel approaches for drug targeting in OA and other osteoarthroses.

BMPs are members of the pleiotropic TGF-β superfamily and are key regulators of skeletal development, osteogenesis and bone healing ([@b26-etm-0-0-6261],[@b27-etm-0-0-6261]). BMP signals are mediated by type I and type II receptors (BMPR1a, BMPR1b and BMPR2) ([@b26-etm-0-0-6261]). BMP signal binding to BMPRs is translocated to the nucleus via Smad signaling (mainly via Smad1,−5 and−8) ([@b28-etm-0-0-6261]). BMP2 significantly promotes bone formation and stimulates osteoblast differentiation of C2C12 cells in conjunction with specific levels of static stretching force ([@b29-etm-0-0-6261]). In addition, it has been confirmed that BMP2 stimulates chondrocyte hypertrophy during chondrogenesis of progenitor ATDC5 cells ([@b30-etm-0-0-6261]), and in the present study it was also demonstrated that BMP2 was downregulated in hypertrophic chondrocytes treated with SIN-1. Therefore, BMP2 is important for the progression of hypertrophy. BMP3 accelerates the differentiation of human mesenchymal stem cells ([@b31-etm-0-0-6261]), and is associated with rabbit articular cartilage repair ([@b32-etm-0-0-6261]). The *BMP5* gene contains an 'injury response' control region, which is activated by multiple types of injury in adult animals ([@b33-etm-0-0-6261]). In the present study, it was demonstrated that BMP2, BMP3, BMPR1a and BMPR1b were downregulated in hypertrophic chondrocytes treated with SIN-1 and BMP5 was upregulated. Combined with the above discussion on Smads, these data suggest that the BMP/SMAD pathway may also take part in an oxidative stress reaction. The increased expression of BMP5 was probably the result of the 'injury response' to oxidative stress.

Matrix metalloproteinases (MMPs) serve important roles in ECM remodeling and degradation. MMPs and their inhibitors (TIMPs) are believed to be associated with the mechanisms underlying KBD ([@b34-etm-0-0-6261]). In the present study, it was demonstrated that the mRNA expression levels of *MMP2*, -*9* and -*10* were downregulated in hypertrophic chondrocytes following treatment with SIN-1. MMP2 and 9 are known to participate in significant degradation of collagen in the muscle of fish ([@b35-etm-0-0-6261]). In the present study, the mRNA expression levels of *Col I* and *Col II* were both increased; thus it was speculated that this increase was caused by downregulation of MMPs. Nevertheless, the mRNA expression level of *Col X*, which is mainly expressed in hypertrophic chondrocytes, was decreased in the present study. This phenomenon may be directly caused by oxidative stress induced by SIN-1. Combined with the literature, the present data suggest that the alteration of *Mmp2,−9*, and -*10* genes led to a change in ECM, which may further affect the cell differentiation.

Integrins are the major family of ECM receptors, which have a vital role in cell-ECM interactions ([@b36-etm-0-0-6261]). Integrins are transmembrane heterodimeric glycoproteins consisting of α and β subunits, combining functions of cell adhesion and bidirectional signal transduction ([@b5-etm-0-0-6261]). In the present study, levels of *α2, αv*, and *β1 integrins* were decreased in hypertrophic chondrocytes following treatment with SIN-1. It has been previously reported that the expression of α2 and α5 integrins increased at later stages of OA in rats, and these levels were associated with the severity of OA ([@b37-etm-0-0-6261]). Additionally α1, α5β1, and αvβ5 integrins have been demonstrated to mediate human chondrocyte adhesion to cartilage ([@b38-etm-0-0-6261]). Increased expression of *Indian hedgehog* (*Ihh*) and *sclerostin* was also observed, as was decreased expression of *Col X*. *Ihh* is expressed in prehypertrophic chondrocytes on growth plates ([@b39-etm-0-0-6261]), whereas Col X was mainly expressed in hypertrophic chondrocytes. Sclerostin is a novel BMP antagonist, which competes with type I and type II BMP receptors ([@b40-etm-0-0-6261]). Thus, SIN-1 may first increase sclerostin and further decrease BMP signaling.

In conclusion, the present study indicated that oxidative stress produced by NO donor induced death of hypertrophic chondrocytes is probably mediated by TGF-β/Smad or BMP/Smad pathways, and dysfunctional pathways may then induce abnormal expression of MMPs and collagens. The present results may provide several novel clues to the molecular mechanisms underlying OA and KBD, which may help to find novel diagnostic and therapeutic targets for these debilitating diseases.

There were, however, certain limitations in the present study: i) KBD does not immediately lead to death, and harvesting the cartilage tissue of patients with KBD is traumatic for patients, so it was very difficult to obtain fresh human cartilage; and ii) there are no functional verification experiments to be conducted. Therefore, further research is required.
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![Establishment of the hypertrophic chondrocyte model. The mRNA expression levels of (A) *Col X* and (B) *Runx2* during the differentiation process were detected by reverse transcription-quantitative polymerase chain reaction. The group treated for 7 days served as a control. Simultaneously, protein expression levels of (C) Col X and (D) Runx2 were assessed via western blotting. Data are expressed as the mean ± standard deviation from three independent experiments. \*P\<0.05 vs. day 7. Col X, type X collagen; Runx2, runt-related transcription factor 2.](etm-16-02-0609-g00){#f1-etm-0-0-6261}

![Viability of hypertrophic chondrocytes treated with SIN-1. (A) Cells were treated with 0, 1, 5 or 10 mM SIN-1 for 4 h. (B) Cells were treated with 0, 1, 2, 3, 4 or 5 mM SIN-1 for 24 h. Data are expressed as the mean ± standard deviation from three independent experiments. \*P\<0.05 vs. 0 mM. SIN-1, 3-morpholinosydnonimine.](etm-16-02-0609-g01){#f2-etm-0-0-6261}

![A scatter plot of 84 genes associated with osteoarthritis. Genes whose expression levels were altered by ≥3-fold were deemed differentially expressed. Upregulated genes are marked with a red circle, whereas downregulated genes are marked with a green circle. Black circles represent genes whose expression was unchanged. SIN-1, 3-morpholinosydnonimine.](etm-16-02-0609-g02){#f3-etm-0-0-6261}

![A histogram presenting mRNA expression levels of 8 selected genes in hypertrophic chondrocytes treated with 3-morpholinosydnonimine. *GAPDH* served as an internal control. Data are expressed as the mean ± standard deviation. PCR, polymerase chain reaction; RT-qPCR, reverse transcription-quantitative PCR; Smad, mothers against decapentaplegic homolog; Col X, type X collagen; MMP, matrix metalloproteinase; Vcam1, vascular cell adhesion molecule 1; Col 2a, collagen, type II, α.](etm-16-02-0609-g03){#f4-etm-0-0-6261}

![Network of protein-protein interactions for differentially expressed genes.](etm-16-02-0609-g04){#f5-etm-0-0-6261}
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###### 

Primers used in reverse transcription-quantitative polymerase chain reaction experiments.

  Genes    Forward primer (5′-3′)    Reverse primer (5′-3′)
  -------- ------------------------- -------------------------
  GAPDH    GGGCTCATGACCACAGTCCATGC   CCTTGCCCACAGCCTTGGCA
  Col X    ACGCATCTCCCAGCACCAGAATC   GGGGCTAGCAAGTGGGCCCT
  Runx2    GGTTGTAGCCCTCGGAGAGG      GCCATGACGGTAACCACAGTC
  Smad1    AAAGACCTGTGGCTTCCGTCT     TTATCGTGGCTCCTTCGTCAG
  Smad2    ATGTCGTCCATCTTGCCATTC     AACCGTCCTGTTTTCTTTAGCTT
  Smad3    GCTGCCCTCCTAGCTCAG        GGTGCTGGTCACTGTCTGTC
  Smad4    GAGAACATTGGATGGACGACT     CACAGACGGGCATAGATCAC
  Col2a1   CCAGCTGACCTCGCCACTGC      GGGTCCAGGCGCACCCTTTT
  MMP10    GCAGCCCATGAACTTGGCCACT    AGGGACCGGCTCCATACAGGG
  Vcam1    GATAGACAGCCCACTAAACGCG    GAATCTCTGGATCCTTGGGG

Col X, type X collagen; Runx2, runt-related transcription factor 2; Smad, mothers against decapentaplegic homolog; Col 2a, collagen, type II, α; MMP10, matrix metalloproteinase 10; Vcam1, vascular cell adhesion molecule 1.

###### 

Significantly downregulated genes in hypertrophic chondrocytes treated with 3-morpholinosydnonimine.

  No.   ID          Symbol    Description                                                                       Fold regulation
  ----- ----------- --------- --------------------------------------------------------------------------------- -----------------
    1   NM_013465   Ahsg      α-2-HS-glycoprotein                                                               −6.19
    2   NM_007553   BMP2      Bone morphogenetic protein 2                                                      −6.11
    3   NM_173404   BMP3      Bone morphogenetic protein 3                                                      −8.52
    4   NM_009758   BMPR1a    Bone morphogenetic protein receptor, type 1A                                      −4.17
    5   NM_007560   BMPR1b    Bone morphogenetic protein receptor, type 1B                                      −7.16
    6   NM_007643   Cd36      Cluster of differentiation 36 antigen                                             −7.26
    7   NM_009866   Cdh11     Cadherin 11                                                                       −3.05
    8   NM_009893   Chrd      Chordin                                                                           −5.28
    9   NM_009925   Col10a1   Collagen, type X, α 1                                                             −4.03
  10    NM_016685   Comp      Cartilage oligomeric matrix protein                                               −5.17
  11    NM_007802   Ctsk      Cathepsin K                                                                       −3.14
  12    NM_010197   Fgf1      Fibroblast growth factor 1                                                        −7.89
  13    NM_010206   Fgfr1     Fibroblast growth factor receptor 1                                               −11.16
  14    NM_010207   Fgfr2     Fibroblast growth factor receptor 2                                               −3.34
  15    NM_010228   Flt1      FMS-like tyrosine kinase 1                                                        −7.41
  16    NM_010512   Igf1      Insulin-like growth factor 1                                                      −3.48
  17    NM_008396   Itga2     Integrin α 2                                                                      −4.76
  18    NM_008402   Itgav     Integrin α V                                                                      −7.52
  19    NM_010578   Itgb1     Integrin β 1 (fibronectin receptor β)                                             −4.20
  20    NM_019471   MMP10     Matrix metalloproteinase 10                                                       −45.25
  21    NM_008610   MMP2      Matrix metalloproteinase 2                                                        −3.66
  22    NM_013599   MMP9      Matrix metalloproteinase 9                                                        −4.66
  23    NM_008689   Nfkb1     Nuclear factor of κ light polypeptide gene enhancer in B cells 1, p105            −3.66
  24    NM_011077   Phex      Phosphate regulating gene with homologies to endopeptidases on the X chromosome   −4.44
  25    NM_008539   Smad1     Mothers against decapentaplegic homolog 1 (Drosophila)                            −3.89
  26    NM_010754   Smad2     Mothers against decapentaplegic homolog 2 (Drosophila)                            −3.10
  27    NM_016769   Smad3     Mothers against decapentaplegic homolog 3 (Drosophila)                            −4.63
  28    NM_008540   Smad4     Mothers against decapentaplegic homolog 4 (Drosophila)                            −4.17
  29    NM_009367   Tgfb2     Transforming growth factor, β 2                                                   −5.31
  30    NM_009370   Tgfbr1    Transforming growth factor, β receptor I                                          −16.00
  31    NM_009371   Tgfbr2    Transforming growth factor, β receptor II                                         −5.70
  32    NM_013693   Tnf       Tumor necrosis factor                                                             −9.19
  33    NM_011613   Tnfsf11   Tumor necrosis factor (ligand) superfamily, member 11                             −4.14
  34    NM_011693   Vcam1     Vascular cell adhesion molecule 1                                                 −6.68

Differentially expressed genes that were deemed differentially expressed by 3-fold or greater are presented.

###### 

Significantly upregulated genes in hypertrophic chondrocytes treated with 3-morpholinosydnonimine.

  No.   ID          Symbol   Description                    Fold regulation
  ----- ----------- -------- ------------------------------ -----------------
    1   NM_007542   Bgn      Biglycan                       5.82
    2   NM_007555   Bmp5     Bone morphogenetic protein 5   7.26
    3   NM_007743   Col1a2   Collagen, type I, α 2          4.08
    4   NM_031163   Col2a1   Collagen, type II, α 1         7.26
    5   NM_010544   Ihh      Indian hedgehog                3.32
    6   NM_024449   Sost     Sclerostin                     4.26

Differentially expressed genes that were deemed differentially expressed by 3-fold or greater are presented.

###### 

Results on top five GO functions and KEGG pathway enrichment analysis of differentially expressed genes.

  Function and pathway   ID            Description                                                    Count in gene set   False discovery rate
  ---------------------- ------------- -------------------------------------------------------------- ------------------- ----------------------
  Biological process     GO: 0001501   Skeletal system development                                    20                  2.03×10^−20^
  (GO)                   GO: 0009888   Tissue development                                             27                  3.18×10^−19^
                         GO: 0001503   Ossification                                                   16                  2.27×10^−18^
                         GO: 0071495   Cellular response to endogenous stimulus                       21                  4.40×10^−18^
                         GO: 0071363   Cellular response to growth factor stimulus                    17                  5.39×10^−18^
  Molecular function     GO: 0046332   Mothers against decapentaplegic homolog binding                10                  5.84×10^−14^
  (GO)                   GO: 0005515   Protein binding                                                32                  4.67×10^−13^
                         GO: 0005160   Transforming growth factor β receptor binding                    8                 1.02×10^−11^
                         GO: 0005126   Cytokine receptor binding                                      10                  1.09×10^−9^
                         GO: 0019838   Growth factor binding                                            8                 1.58×10^−9^
  Cellular component     GO: 0005615   Extracellular space                                            20                  2.99×10^−13^
  (GO)                   GO: 0044421   Extracellular region part                                      26                  2.01×10^−10^
                         GO: 0005576   Extracellular region                                           27                  3.32×10^−10^
                         GO: 0031012   Extracellular matrix                                           12                  3.32×10^−10^
                         GO: 0005578   Proteinaceous extracellular matrix                             11                  1.35×10^−9^
  KEGG pathways          4350          Transforming growth factor-β signaling pathway                 13                  1.50×10^−20^
                         5200          Pathways in cancer                                             17                  2.04×10^−19^
                         4390          Hippo signaling pathway                                        12                  1.87×10^−15^
                         5205          Proteoglycans in cancer                                        12                  1.53×10^−13^
                         4151          Phosphoinositide 3-kinase-protein kinase B signaling pathway   12                  2.49×10^−11^

GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

[^1]: Contributed equally
